Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
|Articles|December 1, 2002
FISH assay may be useful monitor of TCC recurrence
Jena, Germany-The fluorescence in situ hybridization (FISH) assay appears to be a useful, noninvasive method to monitor for tumor recurrence in patients with transitional cell carcinoma of the bladder, according to European researchers.
Advertisement
Advertisement
Related to this article
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Advertisement
Advertisement